Pavmed Inc (PAVM) Stock Price, Quote & News

Company Profile

PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precance...

Industry: Medical Devices

Sector: Healthcare

Phone: 917 813 1828

Website: www.pavmed.com

Address:

360 Madison Avenue, 25th Floor, New York, United States

xx007xx Feb. 4 at 9:24 PM

$PAVM $LUCD Dave is crying… https://ir.pavmed.com/2026-02-04-PAVmed-Closes-Preferred-Stock-and-Senior-Secured-Note-Financings,-Eliminating-All-Previously-Outstanding-Convertible-Securities

1 · Reply

Nesabbah Feb. 4 at 8:45 PM

$PAVM small cap usually react later. $25 is for sure

0 · Reply

Investor_Scale Feb. 4 at 7:42 PM

$PAVM is going to fill gap to 12+ Mark My words

0 · Reply

VinnyG55 Feb. 4 at 6:57 PM

$PAVM While this has been disappointing, a curious thing I see is the strongest cup and handle formation. Right out of a text book. But I'm still mad.

0 · Reply

SqueezzChamber Feb. 4 at 6:56 PM

If you’ve ever wanted to catch a short squeeze early instead of watching it rip after the fact, this group is built for that. Sharing momentum, setups, and what we’re watching as it develops, not when it’s already gone. Click link and join for Free ⭐ limited spots $QSI $PAVM $USAS $IOVA ""

0 · Reply

MagiCarpX Feb. 4 at 5:27 PM

$PAVM market is very red- it bodes well this has done well despite everything

0 · Reply

FlashMcGash Feb. 4 at 5:09 PM

$PAVM another solid move this morning. Lets keep it up

0 · Reply

Zeeshan98 Feb. 4 at 3:58 PM

$PAVM Usually don’t like throwing price targets out there but $40-$50

2 · Reply

JRINPHX Feb. 4 at 3:38 PM

$PAVM what a crack up. They dump 30M on you and the price goes up? Get ready for a big short

1 · Reply

Tom__Brady Feb. 4 at 3:35 PM

$LUCD $PAVM @dmc4321 remember how for a year+ you posted this about Ayrton and then not even one semblance of this idiocy came true? Please just stop…🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣

1 · Reply

PAVmed Closes Preferred Stock and Senior Secured Note Financings, Eliminating All Previously Outstanding Convertible Securities

LUCD

Jan 21, 2026, 3:40 PM EST - 14 days ago

Should you chase the rally in PAVmed stock after it quadrupled on Wednesday?

Jan 21, 2026, 8:00 AM EST - 14 days ago

Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for EsoGuard®

LUCD

Dec 30, 2025, 9:01 AM EST - 5 weeks ago

PAVmed Announces Reverse Stock Split

Dec 9, 2025, 8:01 AM EST - 2 months ago

Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection

LUCD

Dec 5, 2025, 11:08 AM EST - 2 months ago

PAVmed Inc. (PAVM) Shareholder/Analyst Call Prepared Remarks Transcript

Nov 20, 2025, 8:15 AM EST - 2 months ago

Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree

LUCD

Nov 13, 2025, 11:31 AM EST - 2 months ago

PAVmed Inc. (PAVM) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 8:15 AM EST - 2 months ago

Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

LUCD

Nov 13, 2025, 8:00 AM EST - 2 months ago

PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results

LUCD

Nov 12, 2025, 8:00 AM EST - 3 months ago

Lucid Diagnostics Provides Business Update and Reports Third Quarter 2025 Financial Results

LUCD

Oct 30, 2025, 8:01 AM EDT - 3 months ago

PAVmed to Hold a Business Update Conference Call and Webcast on November 13, 2025

LUCD

Oct 29, 2025, 8:01 AM EDT - 3 months ago

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025

LUCD

Oct 15, 2025, 8:01 AM EDT - 4 months ago

Lucid Diagnostics to Participate in the 2025 Maxim Growth Summit

LUCD

Oct 7, 2025, 8:01 AM EDT - 4 months ago

PAVmed Subsidiary, Veris Health and The Ohio State University Comprehensive Cancer Center Launch Commercial Phase of Strategic Partnership Agreement

Sep 16, 2025, 8:01 AM EDT - 5 months ago

Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs

LUCD

Sep 11, 2025, 9:17 AM EDT - 5 months ago

Lucid Diagnostics Announces Closing of Public Offering of Common Stock

LUCD

Sep 10, 2025, 8:00 AM EDT - 5 months ago

Lucid Diagnostics Announces Pricing of Public Offering of Common Stock

LUCD

Sep 9, 2025, 4:01 PM EDT - 5 months ago

Lucid Diagnostics Announces Proposed Public Offering of Common Stock

LUCD

Sep 5, 2025, 9:16 AM EDT - 5 months ago

Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025

LUCD

Aug 27, 2025, 8:00 AM EDT - 5 months ago

Lucid Diagnostics to Participate in the Cantor Global Healthcare Conference 2025

LUCD

Aug 26, 2025, 8:01 AM EDT - 5 months ago

PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology

LUCD

Aug 14, 2025, 8:00 AM EDT - 6 months ago

PAVmed Provides Business Update and Reports Second Quarter 2025 Financial Results

LUCD

Aug 13, 2025, 8:00 AM EDT - 6 months ago

Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results

LUCD

Aug 5, 2025, 8:00 AM EDT - 6 months ago

Lucid Diagnostics to Participate in Upcoming Investor Conferences

LUCD

Jul 31, 2025, 8:01 AM EDT - 6 months ago

PAVmed to Hold a Business Update Conference Call and Webcast on August 14, 2025

LUCD

Jul 30, 2025, 8:01 AM EDT - 6 months ago

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025

LUCD

Jul 30, 2025, 8:00 AM EDT - 6 months ago

PAVmed Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

LUCD

Jul 16, 2025, 7:31 AM EDT - 7 months ago

MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test

LUCD

Jun 24, 2025, 8:01 AM EDT - 8 months ago

PAVmed Subsidiary Veris Health Completes $2.5 Million Direct Equity Financing

Jun 18, 2025, 12:02 PM EDT - 8 months ago

Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test

LUCD

Jun 3, 2025, 8:31 AM EDT - 8 months ago

PAVmed Subsidiary, Veris Health, Enters into Strategic Partnership Agreement with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

May 27, 2025, 7:31 AM EDT - 9 months ago

Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes

LUCD

May 15, 2025, 1:58 PM EDT - 9 months ago

PAVmed Inc. (PAVM) Q1 2025 Earnings Call Transcript

May 15, 2025, 8:01 AM EDT - 9 months ago

PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results

LUCD

May 14, 2025, 8:01 AM EDT - 9 months ago

Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results

LUCD

May 1, 2025, 8:31 AM EDT - 9 months ago

PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025

LUCD

Apr 30, 2025, 8:31 AM EDT - 10 months ago

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025

LUCD

Apr 24, 2025, 8:01 AM EDT - 10 months ago

NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD

LUCD

Apr 3, 2025, 9:00 AM EDT - 10 months ago

Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

LUCD

Mar 27, 2025, 8:01 AM EDT - 11 months ago

Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology

LUCD

Mar 25, 2025, 11:08 AM EDT - 11 months ago

PAVmed Inc. (PAVM) Q4 2024 Earnings Call Transcript

Mar 25, 2025, 8:01 AM EDT - 11 months ago

PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 24, 2025, 8:01 AM EDT - 11 months ago

Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

LUCD

Mar 20, 2025, 8:31 AM EDT - 11 months ago

Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening

LUCD

Mar 18, 2025, 8:31 AM EDT - 11 months ago

Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication

LUCD

Mar 13, 2025, 7:36 AM EDT - 11 months ago

Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test

LUCD

Mar 10, 2025, 9:01 AM EDT - 11 months ago

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025

LUCD

Mar 5, 2025, 4:45 PM EST - 1 year ago

Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering

LUCD

Mar 4, 2025, 8:25 AM EST - 1 year ago

Lucid Diagnostics Announces $15.3 Million Registered Direct Offering

LUCD

xx007xx Feb. 4 at 9:24 PM

$PAVM $LUCD Dave is crying… https://ir.pavmed.com/2026-02-04-PAVmed-Closes-Preferred-Stock-and-Senior-Secured-Note-Financings,-Eliminating-All-Previously-Outstanding-Convertible-Securities

1 · Reply

Nesabbah Feb. 4 at 8:45 PM

$PAVM small cap usually react later. $25 is for sure

0 · Reply

Investor_Scale Feb. 4 at 7:42 PM

$PAVM is going to fill gap to 12+ Mark My words

0 · Reply

VinnyG55 Feb. 4 at 6:57 PM

$PAVM While this has been disappointing, a curious thing I see is the strongest cup and handle formation. Right out of a text book. But I'm still mad.

0 · Reply

SqueezzChamber Feb. 4 at 6:56 PM

0 · Reply

MagiCarpX Feb. 4 at 5:27 PM

$PAVM market is very red- it bodes well this has done well despite everything

0 · Reply

FlashMcGash Feb. 4 at 5:09 PM

$PAVM another solid move this morning. Lets keep it up

0 · Reply

Zeeshan98 Feb. 4 at 3:58 PM

$PAVM Usually don’t like throwing price targets out there but $40-$50

2 · Reply

JRINPHX Feb. 4 at 3:38 PM

$PAVM what a crack up. They dump 30M on you and the price goes up? Get ready for a big short

1 · Reply

Tom__Brady Feb. 4 at 3:35 PM

1 · Reply

GJ_Rockabilt Feb. 4 at 3:24 PM

$PAVM CLEARLY, this is NOT $LUCD .

0 · Reply

GJ_Rockabilt Feb. 4 at 3:21 PM

$PAVM Well it SHOULD, anyways. I think they might do BETTER than that.

0 · Reply

dmc4321 Feb. 4 at 3:16 PM

$PAVM & $LUCD I always look at LUCD and PAVM through the lens of Lishan and Dennis taking $720K each from them thus ensuring a top 1% Lifestyle for a BOTTOM 1% performance. The cost of their annual salaries if it was an annuity payment would be around a $12M annuity EACH. this financing was done to protect their Salaries not your interest IMO. As LUCD will be in breech on May 23rd 2026 and can not cure that breech as there is a bar on any form of prepayment before 2029 this proects Dennis and Lishan when that breech occurs.

1 · Reply

topstockalerts Feb. 4 at 3:01 PM

$PAVM Can it keep running from here? Buyers remain aggressive. Momentum still supports higher prices.

0 · Reply

dmc4321 Feb. 4 at 2:57 PM

$PAVM & $LUCD A prompt. It is UGLY Role: Act as a Series 7/63 Financial Advisor and a Distressed Debt Workout Specialist.Objective: Analyze the PAVmed (PAVM) February 3, 2026, 8-K filing and the Lucid Diagnostics (LUCD) Ninth Amendment to the Management Services Agreement (MSA).Core Assumption: The CEO and CFO are motivated by income preservation rather than equity protection, given their negligible personal shareholdings. Analysis Task 1: The Entrenchment Mechanics Outline how the current financing terms prioritize management’s salary over common shareholder equity: The "Key Man" Poison Pill: Explain how the 2026 Note’s "Event of Default" trigger upon the removal of the CEO/CFO weaponizes the debt against any activist shareholder or board-led termination. The MSA Liquidity Siphon: Detail the Ninth Amendment to the MSA which mandates a $1.05M/month cash payment from LUCD to PAVM, ensuring a pipeline of cash for payroll even as the subsidiary approaches a May 22, 2026, covenant breach.

1 · Reply

Max85 Feb. 4 at 2:52 PM

$PAVM Higher lows, higher highs. This is a coiled spring. No more Preferred stock and convertible debt overhang. Looking forward to the 8k for more details. Let’s go!

0 · Reply

Zeeshan98 Feb. 4 at 2:50 PM

$PAVM on the move

0 · Reply

MagiCarpX Feb. 4 at 2:42 PM

$PAVM

0 · Reply

MagiCarpX Feb. 4 at 2:38 PM

$PAVM let’s see this news spark some new growth

0 · Reply

GJ_Rockabilt Feb. 4 at 2:25 PM

They know how to SQUEEZE over at $PAVM. Watch & Learn. All welcome to join in the festivities!

1 · Reply

vvvvvvrebel89130 Feb. 4 at 2:22 PM

$PAVM grest move tying warrant conversion to positive Medicare coverage includes warrants exercisable for up to an additional $30 million upon publication of a positive draft EsoGuard Medicare local coverage determination

1 · Reply

DirkDarwin Feb. 4 at 2:12 PM

$PAVM Just a matter of time...

0 · Reply

Market Cap	7.62M
Revenue (ttm)	3.00M
Net Income (ttm)	39.79M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	1,326.33%
Debt to Equity Ratio	0.00

Volume	567,929
Avg Vol	1,204,214
Day's Range	N/A - N/A
Shares Out	984,000.00
Stochastic %K	40%
Beta	1.10
Analysts	Sell
Price Target	$285.25